Skip to content
StackItSmart
CCase reports / series

TUDCA

Tauroursodeoxycholic Acid

TUDCA (tauroursodeoxycholic acid) is the taurine-conjugated form of ursodeoxycholic acid (UDCA), a naturally occurring hydrophilic bile acid. It is sold as a dietary supplement marketed for "liver support," and in the performance/anabolic-steroid community it is widely taken during oral 17-alpha-alkylated steroid cycles in the belief that it protects the liver. There is essentially no human evidence that TUDCA prevents or treats anabolic-androgenic-steroid-induced cholestatic liver injury; that specific use is extrapolated from bile-acid pharmacology and animal models (evidence grade D). The strongest human data for TUDCA itself come from a single small 4-week randomized trial in obese adults (improved liver/muscle insulin sensitivity) and from a trial of a combination product (sodium phenylbutyrate + taurursodiol) in ALS, not TUDCA monotherapy. Its parent compound UDCA is a licensed drug for cholestatic liver disease and gallstones. TUDCA is not FDA-approved as a drug in the US; high oral doses commonly cause diarrhea and GI upset; it is contraindicated in complete biliary obstruction; and taking it as "liver insurance" can create false reassurance that leads users to run hepatotoxic oral steroids they should not. TUDCA is not a substitute for stopping a hepatotoxic agent, bloodwork, or clinician care.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
Not precisely cha…
Route
Oral
Evidence
C
Active
Dosed once or twice dai…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not precisely characterized in supplement users; as a bile acid it undergoes rapid first-pass hepatic uptake and enterohepatic recirculation with a short plasma residence (hours). No formal human elimination half-life is established for oral supplement dosing.
Pharmacology

Mechanism of action

TUDCA is a hydrophilic bile acid that acts through several linked mechanisms. (1) Chemical/pharmacological chaperone: it reduces endoplasmic reticulum (ER) stress and improves protein folding, a mechanism demonstrated in obese-mouse models and invoked in a human insulin-sensitivity RCT (Kars 2010, PMID 20522594). (2) Bile-acid pool modulation: given orally it is well absorbed (~65%) and enriches bile with the less-cytotoxic UDCA/taurine-conjugated species, diluting and displacing toxic hydrophobic bile acids and exerting a choleretic effect (Rudolph 2002, PMID 12190957). (3) Anti-apoptotic/mitochondrial stabilization: in animal models it inhibits translocation of the pro-apoptotic protein Bax to mitochondria and reduces hepatocyte apoptosis (Ishigami 2001, PMID 11740392, rat). These anti-apoptotic and anti-ER-stress actions are also the rationale for its neuroprotective use in the ALS combination product (Paganoni 2020, PMID 32877582), though that trial cannot isolate TUDCA's contribution.
Kinetics

Pharmacokinetics

Half-life

Not precisely characterized in supplement users; as a bile acid it undergoes rapid first-pass hepatic uptake and enterohepatic recirculation with a short plasma residence (hours). No formal human elimination half-life is established for oral supplement dosing.

Active duration

Dosed once or twice daily in human trials (e.g., 1,750 mg/day; ALS combination product dosed once then twice daily), consistent with a functional duration requiring at least daily administration.

Route

Oral (capsule/powder) in supplement and most trial use; intravenous forms used in some research/hospital settings. This section is for monitoring and washout planning, not for evading any testing.

Metabolism & clearance

Absorbed ~65% orally (human data, Rudolph 2002, PMID 12190957); taken up by the liver, conjugated with taurine/glycine, secreted in bile, and recirculated enterohepatically. Gut bacteria deconjugate and can biotransform it toward UDCA and, further, to lithocholic acid; excretion is predominantly biliary/fecal.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • In a small 4-week RCT in obese adults (n=20), TUDCA 1,750 mg/day increased hepatic and skeletal-muscle insulin sensitivity by ~30% and enhanced muscle insulin signaling, without changing adipose-tissue insulin sensitivity or measured muscle/adipose ER-stress markers (Kars 2010, PMID 20522594)
  • As part of a fixed combination with sodium phenylbutyrate (taurursodiol 1 g/day component), it was associated with slower functional decline over 24 weeks in early ALS; TUDCA's independent effect cannot be separated from phenylbutyrate (Paganoni 2020, PMID 32877582)
  • Choleretic effect and enrichment of bile with UDCA/taurine-conjugated bile acids after oral dosing (Rudolph 2002, PMID 12190957)
  • Hepatoprotective and anti-apoptotic effects (reduced transaminases, reduced hepatocyte apoptosis) demonstrated in animal liver-injury models but not confirmed for human anabolic-steroid liver injury (Ishigami 2001, PMID 11740392, preclinical)
  • In neonates, enteral TUDCA did not prevent or ameliorate parenteral-nutrition-associated cholestasis, illustrating that a hepatoprotective rationale does not guarantee clinical benefit (Heubi 2002, DOI 10.1067/mpd.2002.125802)
Safety

Adverse effects by system

Cardiovascular

No known direct cardiovascular effects and no human cardiovascular outcome data for TUDCA. Absence of reported harm is not proof of safety.

Hepatic

Generally regarded as hepatoprotective/well tolerated in trials; it is a hydrophilic bile acid, not a hepatotoxin at studied doses. However, a bacterial metabolite (lithocholic acid) is theoretically cholestatic/hepatotoxic, and there is no human evidence that TUDCA protects the liver against anabolic-steroid injury. Do not interpret TUDCA as making a hepatotoxic oral steroid safe.

Endocrine / HPTA

Not a hormonal agent; no HPTA suppression. The only relevant endocrine-metabolic effect is improved hepatic/muscle insulin sensitivity in one small RCT (Kars 2010, PMID 20522594). No adverse endocrine signal reported.

Reproductive

No adequate human reproductive/fertility safety data for TUDCA; safety in pregnancy and lactation is not established. Bile-acid/PCOS links in the literature are largely mechanistic/preclinical and do not establish reproductive effects of TUDCA supplementation.

Neuropsychiatric

No known psychiatric adverse effects and no adequate human data; despite CNS/neuroprotective interest, no psychiatric safety signal has been characterized for TUDCA monotherapy.

Renal

No known renal effects and no adequate human renal safety data.

Hematologic

No known hematologic adverse effects and no adequate human data.

Dermatologic

No known dermatologic adverse effects and no adequate human data.

Recovery

HPTA suppression & recovery

Suppression: None — TUDCA is a bile acid, not a hormone or SERM, and has no known effect on the hypothalamic-pituitary-testicular/gonadal axis

No HPTA suppression to recover from. TUDCA is not a hormonal ancillary and should not be relied upon for hormonal recovery. Any concern about HPTA suppression (e.g., from concurrent anabolic steroids) should be evaluated with bloodwork and managed by an endocrinologist; a single-agent, clinician-directed approach is appropriate and dual-SERM self-treatment is not endorsed here.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Liver panel / LFTs (ALT, AST, ALP, GGT)Total and direct (conjugated) bilirubinSerum bile acids where cholestasis is suspectedFasting glucose/HbA1c if used in a metabolic contextBaseline labs before starting any hepatotoxic co-administered agent, then periodic repeat

Cadence: Obtain a baseline before use; if used alongside a hepatotoxic oral agent, check LFTs and bilirubin roughly every 3-4 weeks during the exposure and any time symptoms appear; recheck after discontinuation to confirm normalization.

Warning signs — seek care
  • Jaundice (yellow skin or eyes)
  • Dark urine or pale/clay-colored stools
  • Persistent right-upper-quadrant abdominal pain
  • Severe or persistent itching (pruritus)
  • Nausea, vomiting, or loss of appetite with fatigue
  • Rising ALT/AST, ALP, or bilirubin on labs — stop the hepatotoxic agent and seek care
  • Persistent or severe diarrhea
Do not use if

Contraindications

  • Complete biliary obstruction (bile acids require patent bile flow; obstruction can worsen injury)
  • Known hypersensitivity to bile acids or to TUDCA/UDCA
  • Acute cholangitis or acute biliary/gallbladder inflammation: requires urgent medical care, not a supplement
  • Pregnancy and breastfeeding (safety not established for TUDCA supplementation)
  • Should not be used as self-treatment for established or suspected steroid-induced jaundice/cholestasis in place of stopping the offending agent and seeking clinician evaluation
  • Existing significant liver disease should be managed by a hepatologist rather than self-supplemented
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Do not treat TUDCA as 'liver insurance' that makes a hepatotoxic oral (17-alpha-alkylated) steroid safe. No human study supports that, and false reassurance can lead to riskier use.
  • The only way to know your liver is coping is bloodwork: get baseline LFTs and bilirubin before any hepatotoxic exposure and recheck every 3-4 weeks and if symptoms arise.
  • Stop the offending hepatotoxic agent and seek medical care immediately if you develop jaundice, dark urine, pale stools, severe itching, right-upper-quadrant pain, or rising liver enzymes/bilirubin. TUDCA is not a rescue treatment.
  • High oral doses commonly cause diarrhea and GI upset; reduce or stop if this occurs.
  • Do not use with complete biliary obstruction or acute biliary infection; these are medical emergencies.
  • Avoid in pregnancy and breastfeeding; safety is not established.
  • Discuss any use with a clinician, especially if you have existing liver, gallbladder, or metabolic disease, or take other medications.
  • TUDCA is not a hormonal agent and does nothing for HPTA recovery. Manage hormonal concerns with an endocrinologist and bloodwork.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    TUDCA 1,750 mg/day for 4 weeks increased hepatic and muscle (not adipose) insulin sensitivity by ~30% in a randomized placebo-controlled trial in 20 obese adults, and was generally well tolerated.

    RCTPMID 20522594 ↗

  2. 02

    TUDCA acts as a chemical chaperone that reduces ER stress and improves protein folding, the mechanistic rationale tested in the human insulin-sensitivity trial.

    RCTPMID 20522594 ↗

  3. 03

    A fixed combination of sodium phenylbutyrate and taurursodiol (TUDCA component 1 g/day) slowed ALSFRS-R functional decline over 24 weeks versus placebo; adverse events were mainly gastrointestinal. TUDCA's independent effect cannot be isolated.

    RCTPMID 32877582 ↗

  4. 04

    Longer-term follow-up of the CENTAUR cohort reported a survival difference associated with the phenylbutyrate-taurursodiol combination.

    CohortPMID 33063909 ↗

  5. 05

    Oral TUDCA is absorbed approximately 65% in humans and enriches bile with UDCA/taurine-conjugated bile acids; absorption and biliary secretion did not differ significantly from UDCA.

    RCTPMID 12190957 ↗

  6. 06

    TUDCA reduces hepatocyte apoptosis and serum transaminases and inhibits Bax translocation to mitochondria in a rat warm ischemia-reperfusion liver-injury model (preclinical mechanism; not human).

    PreclinicalPMID 11740392 ↗

  7. 07

    Enteral TUDCA (30 mg/kg/day) did NOT prevent or ameliorate parenteral-nutrition-associated cholestasis in neonates, showing a hepatoprotective rationale does not guarantee clinical benefit.

    RCTDOI 10.1067/mpd.2002.125802 ↗

  8. 08

    No adequate human evidence exists that TUDCA prevents or treats anabolic-androgenic-steroid-induced cholestatic liver injury; this use is extrapolated from bile-acid pharmacology and animal data.

    PreclinicalPMID 11740392 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice